Antibiotic susceptibility pattern and ESBL prevalence in nosocomial Escherichia coli from urinary tract infections in Pakistan

African Journal of Biotechnology

Volumn 8, Issue 16, 2009, Pages 3921-3926

  Ullah, Farhat ^a   Malik, Salman Akbar ^a   Ahmed, Jawad ^b  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b KHYBER TEACHING HOSPITAL   (Pakistan)

Author keywords

Antibiotic resistance; Escherichia coli; Extended Spectrum Lactamase; Urinary tract infections

Indexed keywords

AMPICILLIN; CEFACLOR; CEFOTAXIME; CEFRADINE; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ENOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; KANAMYCIN; MEROPENEM; NALIDIXIC ACID; OFLOXACIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; DISK DIFFUSION; DRUG SCREENING; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; INFANT; MALE; MULTIDRUG RESISTANCE; NEWBORN; PAKISTAN; PREVALENCE; URINARY TRACT INFECTION;

ESCHERICHIA COLI;

EID: 70349188307     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Akram M, Shahid M, Khan AU (2007). Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Ann. Clin. Microbiol. Antimicrob. 6: 4.
2. Ali AM, Rafi S, Qureshi AH (2004). Frequency of extended spectrum b lactamase producing gram negative bacilli among clinical isolates at clinical laboratories of Army Medical College, Rawalpindi. J. Ayub. Med. Coll. Abbottabad 16(1): 35-37.
3. Babini GS, Livermore DM (2000). Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J. Antimicrob. Chemother. 45(2): 183-189.
4. Babypadmini S, Appalaraju B (2004). Extended spectrum -lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae - Prevalence and susceptibility pattern in a tertiary care hospital. Indian J. Med. Microbiol. 22(3): 172-174.
5. Bonsu BK, Shuler L, Sawicki L, Dorst P, Cohen DM (2006). Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections. Acad Emerg. Med. 13(1): 76-81.
6. CLSI (2006). Clinical and Laboratory Standards Institute (CLSI): Performance Standard for Antimicrobial Susceptibility Testing. 16th Informational supplement. CLSI document M100-S16.
7. Colodner R, Samra Z, Keller N, Sprecher H, Block C, Peled N, Lazarovitch T, Bardenstein R, Schwartz-Harari O, Carmeli Y (2007). First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagn. Microbiol. Infect Dis. 57(2): 201-205.
8. Cox CE (1988). Nosocomial urinary tract infections. Urol. 32(3): 210-215.
9. El Astal Z (2005). Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Gaza Strip, Palestine. J. Biomed Biotechnol. (3): 238-241. (Pubitemid 43120930)
10. Garcia Garcia MI, Munoz Bellido JL, Garcia Rodriguez JA (2007). In vitro susceptibility of community-acquired urinary tract pathogens to commonly used antimicrobial agents in Spain: a comparative multicenter study (2002-2004). J. Chemother. 19(3): 263-270.
11. Gonzalez CM, Schaeffer AJ (1999). Treatment of urinary tract infection: what's old, what's new, and what works. World J. Urol. 17(6): 372-382.
12. Gonzalez LS, Spencer JP (1998). Aminoglycosides: a practical review. Am. Fam. Physician 58(8): 1811-1820.
13. Gordon KA, Jones RN (2003). Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. 45(4): 295-301.
14. Griebling TL (2005). Urologic diseases in America project: trends in resource use for urinary tract infections in women. J. Urol. 173(4): 1281-1287. (Pubitemid 40380555)
15. Gul N, Mujahid TY, Ahmed S (2004). Isolation, Identification and Antibiotic Resistance Profile of Indigenous Bacterial Isolates from Urinary Tract Infections Patients. Pak. J. Biological Sci. 7(12): 2051-2054.
16. Gupta K, Hooton TM, Stamm WE (2001). Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Int. Med. 135(1): 41-50.
17. Hammer DA, Dongol S, Anderson TP, Wong JS, Werno AM, Murdoch DR (2007). High prevalence of extended-spectrum β-lactamase-producing Enterobac-teriaceae in Nepal. Int. J. Antimicrob. Agents 30(5): 471-472.
18. Hankook REW (1998). Resistance Mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-Negative Bacteria. Clin. Infect Dis. 27: S93-99.
19. Hasan AS, Nair D, Kaur J, Baweja G, Deb M, Aggarwal P (2007). Resistance patterns of urinary isolates in a tertiary Indian hospital. J. Ayub. Med. Coll. Abbottabad. 19(1): 39-41.
20. Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W (2001). Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J. Antimicrob. Chemother. 47(6): 773-780.
21. Huovinen P (1998). Control of antimicrobial resistance: time for action. British Med. J. 317: 613-614. (Pubitemid 28403480)
22. Jabeen K, Zafar A, Hasan R (2003). Comparison of double disc and combined disc method for the detection of extended spectrum β lactamases in enterobacteriaceae. J. Pak. Med. Assoc. 53(11): 534-536.
23. Jabeen K, Zafar A, Hasan R (2005). Frequency and sensitivity pattern of Extended Spectrum β Lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. J. Pak. Med. Assoc. 55(10): 436-439.
24. Jamal W, Rotimi VO, Khodakhast F, Saleem R, Pazhoor A Al Hashim G (2005). Prevalence of extended-spectrum β-lactamases in Enterobacteriaceae, Pseudomonas and Stenotrophomonas as determined by the VITEK 2 and E test systems in a Kuwait teaching hospital. Med. Princ. Pract. 14(5): 325-331.
25. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM Zhanel GG (2006). Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob. Agents Chemother. 50(6): 2251-2254.
26. Kass EH (1956). Asymptomatic infections of the urinary tract. Trans. Assoc. Am. Physicians 69: 56-64.
27. Kjerulf A, Hansen DS, Sandvang D, Hansen F Frimodt-Moller N (2008). The prevalence of ESBL-producing E. coli and Klebsiella strains in the Copenhagen area of Denmark. APMIS 116(2): 118-124.
28. Lucet JC, Decre D, Fichelle A, Joly-Guillou ML, Pernet M, Deblangy C, Kosmann MJ, Regnier B (1999). Control of a prolonged outbreak of extended-spectrum β-lactamase-producing enterobacteriaceae in a university hospital. Clin. Infect Dis. 29(6): 1411-1418.
29. Mathai E, Grape M, Kronvall G (2004). Integrons and multidrug resistance among Escherichia coli causing community-acquired urinary tract infection in southern India. APMIS 112(3): 159-164.
30. Mathur P, Kapil A, Das B, Dhawan B (2002). Prevalence of extended spectrum β lactamase producing gram negative bacteria in a tertiary care hospital. Indian J. Med. Res. 115: 153-157.
31. Matute AJ, Hak E, Schurink CA, McArthur A, Alonso E, Paniagua M, Van Asbeck E, Roskott AM, Froeling F, Rozenberg-Arska M, Hoepelman IM (2004). Resistance of uropathogens in symptomatic urinary tract infections in Leon, Nicaragua. Int. J. Antimicrob. Agents 23(5): 506-509.
32. Mazzulli T, Skulnick M, Small G, Marshall W, Hoban DJ, Zhanel GG, Finn S, Low DE (2001). Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents. Can. J. Infect Dis. 12(5): 289-292.
33. Mehrgan H, Rahbar M (2008). Prevalence of extended-spectrum β-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran. Int. J. Antimicrob. Agents 31(2): 147-151.
34. Melzer M, Petersen I (2007). Mortality following bacteraemic infection caused by extended spectrum b-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J. Infect 55(3): 254-259. (Pubitemid 47244918)
35. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ (1993). Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann. Int. Med. 119(5): 353-358.
36. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ (1997). The most frequent aminoglycoside resistance mechanisms - changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin. Infect Dis. 24(1): S46-62.
37. Noor N, Ajaz M, Rasool SA, Pirzada ZA (2004). Urinary tract infections associated with multidrug resistant enteric bacilli: characterization and genetical studies. Pak. J. Pharm. Sci. 17(2): 115-123.
38. Paterson DL (2000). Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum b-lactamases (ESBLs). Clin. Microbiol. Infect 6(9): 460-463.
39. Paterson DL, Bonomo RA (2005). Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4): 657-686.
40. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, Ariza J, Gudiol F (1998). Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum b-lactamases. Antimicrob. Agents Chemother. 42(1): 53-58.
41. Philippon A, Labia R, Jacoby G (1989). "Extended-spectrum β-lactamases." Antimicrob. Agents Chemother. 33(8): 1131-1136.
42. Quale JM, Landman D, Bradford PA, Visalli M, Ravishankar J, Flores C, Mayorga D, Vangala K, Adedeji A (2002). Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin. Infect Dis. 35(7): 834-841.
43. Rahman MM, Haq JA, Hossain MA, Sultana R, Islam F, Islam AH (2004). Prevalence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an urban hospital in Dhaka, Bangladesh. Int. J. Antimicrob. Agents 24(5): 508-510.
44. Rahman S, Hameed A, Roghani MT, Ullah Z (2002). Multidrug resistant neonatal sepsis in Peshawar, Pakistan. Arch Dis. Child. Fetal. Neonatal Ed. 87(1): F52-54.
45. Ram S, Gupta R Gaheer M (2000). Emerging antibiotic resistance among the uropathogens. Indian J. Med. Sci. 54(9): 388-394.
46. Sahm DF, Thornsberry C, Mayfield DC, Jones ME Karlowsky JA (2001). Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob. Agents Chemother. 45(5): 1402-1406.
47. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y (2006). Clinical and economic impact of bacteremia with extended- spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 50(4): 1257-1262.
48. Shah AA, Hasan F, Ahmed S, Hameed A (2003). Prevalence of extended spectrum b-lactamases in nosocomial and outpatients (Ambulatory). Pak. J. Med. Sci. 19(3): 187-191.
49. Shehabi AA, Mahafzah AM, Al-Khalili KZ (2004). Antimicrobial resistance and plasmid profiles of urinary Escherichia coli isolates from Jordanian patients. East Mediterr. Health J. 10(3): 322-328.
50. Stamm WE, Norrby SR (2001). Urinary tract infections: disease panorama and challenges. J. Infect Dis. 183(1): S1-4.
51. Stobberingh EE, Arends J, Hoogkamp-Korstanje JA, Goessens WH, Visser MR, Buiting AG, Debets-Ossenkopp YJ, van Ketel, RJ, van Ogtrop ML, Sabbe LJ, Voorn GP, Winter HL, van Zeijl JH (1999). Occurrence of extended-spectrum blactamases (ESBL) in Dutch hospitals. Infection 27(6): 348-354.
52. Taneja N, Rao P, Arora J, Dogra A (2008). Occurrence of ESBL & Amp-C β-lactamases & susceptibility to newer antimicrobial agents in complicated UTI. Indian J. Med. Res. 127(1): 85-88.
53. Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U (2004). Evaluation of extended spectrum β lactamase in urinary isolates. Indian J. Med. Res. 120(6): 553-556.
54. Trevor AJ, Katzung BG, Masters SB (2001). Katzungs Pharmacology: Examination and Board Review. New York, McGraw-Hill/Appleton & Lange.
55. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE (1999). Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect Dis. 29(4): 745-758.
56. Yuksel S, Ozturk B, Kavaz A, Ozcakar ZB, Acar B, Guriz H, Aysev D, Ekim M Yalcinkaya F (2006). Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections. Int. J. Antimicrob. Agents 28(5): 413-416.
57. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z Goldmann DA (2005). Hospital-acquired neonatal infections in developing countries. Lancet 365(9465): 1175-1188. (Pubitemid 40417568)